EKF Diagnostics Holdings PLC Director/PDMR Shareholding (5538P)

TIDMEKF

RNS Number : 5538P

EKF Diagnostics Holdings PLC

21 June 2022

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Director/PDMR Shareholding

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business , announces that it has been notified that on 20 June 2022 Julian Baines, Non-Executive Deputy Chairman, purchased a total of 11,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 32.596 pence per Ordinary Share.

Following this transaction, Julian Baines' total direct and indirect interest in the Group is 1,616,288 Ordinary Shares representing approximately 0.36% of the Group's total issued share capital.

The Notification of Dealing Form required in accordance with UK MAR is set out below.

 
EKF Diagnostics Holdings plc                                  www.ekfdiagnostics.com 
Mike Salter, CEO                                            Tel: [phone] 
Marc Davies, CFO 
 
Singer Capital Markets (Nominated Adviser &                 Tel: [phone] 
 Joint Broker) 
Aubrey Powell / George Tzimas 
 
Investec Bank plc (Joint Broker)                            Tel: [phone] 
Gary Clarence / Daniel Adams / Ben 
 Farrow 
 
Walbrook PR Limited                   Tel: [phone] or [e-mail] 
Paul McManus / Lianne Applegarth          Mob: [phone] 
                                                                                 303 
 
 
 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                  Julian Baines 
      ------------------------------------  -------------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------------------- 
 a)    Position/status                       Non-Executive Deputy Chairman 
      ------------------------------------  -------------------------------------- 
 b)    Initial notification                  Initial Notification 
        /Amendment 
      ------------------------------------  -------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ---------------------------------------------------------------------------- 
 a)    Name                                  EKF Diagnostics Holdings plc 
      ------------------------------------  -------------------------------------- 
 b)    LEI                                   213800DXTF3EAUK1AR05 
      ------------------------------------  -------------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ---------------------------------------------------------------------------- 
 a)    Description of the                    Ordinary Shares of GBP0.01 each 
        financial instrument, 
        type of instrument 
 
       Identification code                   GB0031509804 
 
 b)    Nature of the transaction             Purchase of Ordinary Shares 
      ------------------------------------  -------------------------------------- 
 c)    Price(s) and volume(s) 
                                             --------------------  ------------- 
                                              Price(s)              Volume(s) 
                                             --------------------  ------------- 
    32.596 pence                                                    11,000 
   --------------------------------------------------------------  ------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                   N/A - Single Transaction 
 
  - Price 
 
 e)    Date of the transaction               20 June 2022 
      ------------------------------------  -------------------------------------- 
 f)    Place of the transaction              London Stock Exchange - AIMX 
      ------------------------------------  -------------------------------------- 
 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

 
 Point-of-Care            Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in 
                          the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's 
                          offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 
                          80,000 
                          hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 
                          100 countries. 
 Central Laboratory       Clinical chemistry, Small lab analysers, Centrifuges 
                          Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor, Glycates Albumin, Glycated Serum Protein, 
                          Nitro-tab, 
                          Procalcitonin 
 Life Sciences            Enzyme fermentation, Custom products and Bulk fermentation 
 Contract Manufacturing   Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits 
 Laboratory Services      In September 2021, EKF completed the acquisition of Advanced Diagnostic Laboratory LLC ("ADL 
                          Health"), a Texas based testing laboratory certified under the Clinical Laboratory 
                          Improvement 
                          Amendments ("CLIA") for high complexity testing. The laboratory provides testing for a 
                          variety 
                          of clinical, forensic and microbiological sample types using a range of analytical 
                          techniques. 
                          This acquisition positions EKF as a leading 'one stop' provider of diagnostic products and 
                          services from sample collection to results. 
 

EKF's growth strategy to 2024 and beyond can be summarised as:

 
 --   continuing innovation in products and services in Point-of-Care, 
       Central Laboratory and Life Sciences leveraging new and existing 
       routes to market and relationships; 
 --   investment in expanded production and kitting capabilities to 
       offer a suite of diagnostic Contract Manufacturing solutions to 
       third party businesses; 
 --   expansion of CLIA Laboratories Testing offering, building on the 
       acquired capabilities in ADL Health; and 
 --   concluding complementary earnings-enhancing acquisitions with 
       key strategic value. 
 

EKF will also continue to generate enhanced shareholder value through:

 
 --   a progressive dividend policy; and 
 --   its agreement with Mount Sinai Innovation Partners ("MSIP"), which 
       allows us advanced access to innovative commercial opportunities 
       and where we can build on the ongoing successes of Renalytix plc, 
       Verici Dx plc and Trellus Health plc. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBCGDLIXDDGDG

(END) Dow Jones Newswires

June 21, 2022 02:00 ET (06:00 GMT)